RVMD vs. RVTY: Revolution Medicines vs. Revvity Stock Comparison

Company Profile

Revolution Medicines (RVMD) and Revvity (RVTY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RVMD is classified in Biotechnology while RVTY is classified in Life Sciences Tools & Services.

Revvity (RVTY) has more than two decades of public-market history since February 21, 1973, whereas Revolution Medicines (RVMD) listed on February 13, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Revvity (RVTY) reports 3.45%, ranking against industry peers normally.

Revvity (RVTY) at 8.61% retains a top-quartile share of revenue as profit, ahead of Revolution Medicines (RVMD) at 0.00%, which keeps about the industry-typical share.

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Revvity (RVTY) reports 17.06%, ranking against industry peers normally.

Profitability Metrics

Growth

Only one side can be read here: Revvity (RVTY) reports revenue growth of 3.67%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Only one side can be read here: Revvity (RVTY) reports EPS growth of -5.91%, ranked against its industry; Revolution Medicines (RVMD) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Revolution Medicines (RVMD) at 8.36 and Revvity (RVTY) at 2.65 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both Revolution Medicines (RVMD) at 0.50 and Revvity (RVTY) at 0.38 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Revolution Medicines (RVMD) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.

Revolution Medicines (RVMD) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Revvity (RVTY) trades at 68.94 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

Revvity (RVTY) at 5.88 prices around its industry’s typical P/S ratio, while Revolution Medicines (RVMD) at 210.51 clears its benchmark range — RVMD looks notably rich on sales.

Revvity (RVTY) at 2.39 sits near its industry’s typical P/B ratio, while Revolution Medicines (RVMD) at 17.31 prices above its benchmark range — RVMD looks rich relative to book.

Valuation Metrics